DelSiTech signs License Agreement with Bayer Innovation
Under the terms of the agreement DelSiTech will receive a signing fee, milestone payments and further royalties for future sales of the products using the DelSiTech technology. The agreement contains also an option for further collaboration.
The DelSiTech ® drug delivery technology is a result of a cross-disciplinary project including researchers from the University of Turku and the Swedish-speaking University in Turku called Åbo Akademi. After the transfer of the technology, DelSiTech has started the industrialization process of the same. According to the compnay, it has been possible to encapsulate and controllably release extremely labile viruses and proteins to clinically useful applications by combining the in depth know-how and IPR of silica chemistry with the newest nano technology.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.